• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ikena Oncology Inc. (Amendment)

    2/14/24 4:48:58 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKNA alert in real time by email
    SC 13G/A 1 d791858dsc13ga.htm SC 13G/A SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1

    (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    (Amendment No. 1)

     

     

    Ikena Oncology, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    45175G108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 45175G108    13 G    Page 2 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 3 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 4 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund VI GP Manager, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 5 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Claudio Nessi

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Switzerland

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 6 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Otello Stampacchia

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Italy

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 7 of 10 Pages

     

     1   

     NAMES OF REPORTING PERSONS

     

     Anne-Mari Paster

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,249,123

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,249,123

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,249,123

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.7% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund VI, L.P. (“Omega Fund”), Omega Fund VI GP, L.P. (“Omega GP”), Omega Fund VI GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.


    CUSIP NO. 45175G108    13 G    Page 8 of 10 Pages

     

    Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”), of Ikena Oncology, Inc. (the “Issuer”).

     

    Item 1(a)

    Name of Issuer:

    Ikena Oncology, Inc. (the “Issuer”)

     

    Item 1(b)

    Address of Issuer’s principal executive offices:

    Ikena Oncology, Inc.

    645 Summer Street, Suite 101

    Boston, MA 02210

     

    Items

    2(a) Name of Reporting Persons filing:

    Omega Fund VI, L.P. (“Omega Fund”)

    Omega Fund VI GP, L.P. (“Omega GP”)

    Omega Fund VI GP Manager, Ltd. (“Omega Ltd”)

    Claudio Nessi (“Nessi”)

    Otello Stampacchia (“Stampacchia”)

    Anne-Mari Paster (“Paster”)

     

    Item 2(b)

    Address or principal business office or, if none, residence:

    The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Nessi, Stampacchia, and Paster, is c/o Omega Fund Management, LLC, 888 Boylston Street, Suite 1111, Boston, MA 02199.

     

    Item 2(c)

    Citizenship:

     

        

    Name

      

    Citizenship or Place of Organization

          Omega Fund    Cayman Islands
       Omega GP    Cayman Islands
       Omega Ltd    Cayman Islands
       Nessi    Switzerland
       Stampacchia    Italy
       Paster    United States of America

     

    Item 2(d)

    Title of class of securities:

    Common Stock

     

    Item 2(e)

    CUSIP No.:

    45175G108

     

    Item 3

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

    Not applicable.

     

    Item 4

    Ownership

    The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2023.


    CUSIP NO. 45175G108    13 G    Page 9 of 10 Pages

     

    Reporting Persons

       Shares of
    Common
    Stock Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class

    (1)
     

    Omega Fund(2)(3)

         2,249,123        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

    Omega GP(2)(3)

         0        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

    Omega Ltd(2)(3)

         0        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

    Nessi(2)(3)

         0        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

    Stampacchia(2)(3)

         0        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

    Paster(2)(3)

         0        0        2,249,123        0        2,249,123        2,249,123        4.7 % 

     

    (1)

    The following percentages are based on 48,258,111 shares of Common Stock outstanding as of November 1, 2023 as set forth in the Issuer’s most recent Form 10-Q for the period ending September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023.

    (2)

    Omega Fund owns 2,249,123 shares of the Common Stock. Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund, and each of Omega GP and Omega Ltd may be deemed to own beneficially the shares held by Omega Fund. Nessi, Stampacchia, and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares of the Issuer’s Common Stock held by Omega Fund except to the extent of his, her or its pecuniary interest therein.

    (3)

    The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    Item 5

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10

    Certifications

    Not applicable.


    CUSIP NO. 45175G108    13 G    Page 10 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:   February 14, 2024
    OMEGA FUND VI, L.P.
    BY:   Omega Fund VI GP, L.P.
    ITS:   GENERAL PARTNER
    BY:   Omega Fund VI GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:   /s/ Otello Stampacchia
      Director
    OMEGA FUND VI GP, L.P.
    BY:   Omega Fund VI GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:   /s/ Otello Stampacchia
      Director
    OMEGA FUND VI GP MANAGER, LTD.
    By:   /s/ Otello Stampacchia
      Director
    /s/ * Otello Stampacchia, as Attorney-in-Fact
    Claudio Nessi
    /s/ Otello Stampacchia
    Otello Stampacchia
    /s/ * Otello Stampacchia, as Attorney-in-Fact
    Anne-Mari Paster
    Get the next $IKNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IKNA

    DatePrice TargetRatingAnalyst
    5/29/2024$8.00 → $2.00Outperform → Neutral
    Wedbush
    9/22/2023$11.00Outperform
    Wedbush
    5/4/2023$18.00Buy
    H.C. Wainwright
    12/23/2021$25.00Buy
    HC Wainwright & Co.
    8/13/2021$30.00 → $27.00Outperform
    Credit Suisse
    More analyst ratings

    $IKNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Yarema Kristin

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 9:30:44 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 9:30:03 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ikena Oncology downgraded by Wedbush with a new price target

    Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

    5/29/24 7:45:06 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Ikena Oncology with a new price target

    Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00

    9/22/23 7:17:31 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Ikena Oncology with a new price target

    H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00

    5/4/23 8:00:07 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    SEC Filings

    View All

    Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    8/1/25 4:59:33 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.

    SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)

    7/30/25 9:28:19 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.

    SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)

    7/29/25 4:53:05 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

    The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) --  Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma

    7/25/25 11:00:00 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

    Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th

    7/15/25 4:15:00 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:47:09 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Leadership Updates

    Live Leadership Updates

    View All

    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

    BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

    7/23/25 9:00:00 AM ET
    $IKNA
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Traws Pharma Announces Management Updates

    Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

    3/28/25 4:30:00 PM ET
    $IKNA
    $IOVA
    $TRAW
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ikena Oncology Reports Second Quarter 2024 Financial Results

    BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood In May 2024, the Company announced the discontinuation of the IK-930 clinical program Corporate Updates In

    8/8/24 4:15:00 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

    SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

    11/13/24 4:05:14 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Ikena Oncology Inc. (Amendment)

    SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

    3/11/24 8:19:04 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKNA
    Financials

    Live finance-specific insights

    View All

    Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

    Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena's acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a com

    8/7/23 7:00:00 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care